Dosimetry Study And Short-term Efficacy Analysis Of Intracavitary/Interstitial Brachytherapy In Cervical Cancer

Objective:Through comparative analysis of the efficacy and safety of traditional intracavitary brachytherapy and intracavitary/interstitial brachytherapy,the feasibility and application value of intracavitary/interstitial brachytherapy in the treatment of cervical cancer are explored,which provides a basis for the choice of brachytherapy.Methods:The clinical data of patients with cervical cancer confirmed by pathology and treated in the department of radiotherapy of the Affiliated Hospital of North Sichuan Medical College from April 2019 to June 2020 were collected.Among them,16 were treated with traditional intracavitary afterloading radiotherapy,14 were treated with intracavitary/interstitial brachytherapy.SPSS software was used to compare and analyze the target dose(HR-CTV D90,HR-CTV D100,IR-CTV D90,IR-CTV D100),the dose of the organs at risk(bladder,rectum,sigmoid D2cc,D0.1cc),short-term efficacy and adverse reactions.Results:1.Comparison of target dose parameters:the target dose of HR-CTV D90 and HR-CTV D100 of intracavitary/interstitial brachytherapy was significantly higher than that of traditional intracavitary brachytherapy,and the difference was statistically significant(P<0.05),but there was no significant difference in IR-CTV D90 and IR-CTV D100 between the two groups of patients(P>0.05).2.Comparison of dose parameters for organs at risk:in intracavitary/interstitial brachytherapy,the dose of bladder D2cc,rectum D2cc and rectum D0.1cc for organs at risk were significantly lower than those of traditional intracavitary afterloading therapy(P<0.05),but there was no significant difference in bladder DO.1cc,sigmoid D2cc and sigmoid D0.1cc(P>0.05).3.Comparison of short-term efficacy:one month after the end of brachytherapy,there was no significant difference between the short-term efficacy of intracavitary/interstitial brachytherapy and traditional intracavitary brachytherapy(P>0.05).4.Comparison of adverse reactions:The occurrence of acute radiation enteritis,and acute radiation cystitis of the two groups was evaluated by RTOG grading standards,and the results showed that there was no significant difference between the two groups(P>0.05).Conclusions:In the brachytherapy of cervical cancer,compared with traditional intracavitary afterloading radiotherapy,intracavitary/interstitial brachytherapy can significantly increase the dose of HR-CTV D90 and HR-CTV D100 in the tumor target area,while reducing the dose of bladder and rectum D2cc.Both of them have similar short-term efficacy,and do not increase the adverse reactions and complications related to radiotherapy.It is a safe and effective new treatment technology.